Risikoabschätzung bei Patienten mit chronischen Atemwegs- und Lungenerkrankungen im Rahmen der SARS-CoV-2-Pandemie

M. Lommatzsch; K. F. Rabe; C. Taube; M. Joest; M. Kreuter; H. Wirtz; T. G. Blum; M. Kolditz; H. Geerdes-Fenge; R. Otto-Knapp; B. Häcker; T. Schaberg; F. C. Ringshausen; C. F. Vogelmeier; N. Reinmuth; M. Reck; J. Gottlieb; S. Konstantinides; F. J. Meyer; H. Worth; W. Windisch; T. Welte; T. Bauer

doi:10.1055/a-1321-3400

Pneumologie 2021; 75(01): 19-30
DOI: 10.1055/a-1321-3400

Stellungnahme der DGP

Risikoabschätzung bei Patienten mit chronischen Atemwegs- und Lungenerkrankungen im Rahmen der SARS-CoV-2-Pandemie^[*]

Stellungnahme der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V. (DGP) mit Unterstützung des Bundesverbands der Pneumologen, Schlaf- und Beatmungsmediziner e. V. (BdP)Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 PandemicStatement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)

M. Lommatzsch

¹Zentrum für Innere Medizin, Abteilung Pneumologie, Universitätsmedizin Rostock, Rostock

,

K. F. Rabe

²LungenClinic Großhansdorf, Großhansdorf

¹⁹Deutsches Zentrum für Lungenforschung

,

C. Taube

³Klinik für Pneumologie, Universitätsmedizin Essen-Ruhrlandklinik, Westdeutsches Lungenzentrum, Essen

,

M. Joest

⁴Lungen- und Allergiezentrum Bonn, Bonn

,

M. Kreuter

⁵Zentrum für interstitielle und seltene Lungenerkrankungen, Pneumologie und Beatmungsmedizin, Thoraxklinik, Universitätsklinikum Heidelberg

¹⁹Deutsches Zentrum für Lungenforschung

,

H. Wirtz

⁶Abt. Pneumologie, Universitätsklinikum Leipzig AöR, Leipzig

,

T. G. Blum

⁷Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin

,

M. Kolditz

⁸Medizinische Klinik 1, Bereich Pneumologie, Universitätsklinikum Carl Gustav Carus, Dresden

,

H. Geerdes-Fenge

⁹Universitätsmedizin Rostock, Zentrum für Innere Medizin, Abteilung für Infektionskrankheiten und Tropenmedizin, Rostock

,

R. Otto-Knapp

¹⁰Dtsch. Zentralkomitee zur Bekämpfung der Tuberkulose, DZK, Berlin

,

B. Häcker

¹⁰Dtsch. Zentralkomitee zur Bekämpfung der Tuberkulose, DZK, Berlin

,

T. Schaberg

¹¹Rotenburg

,

F. C. Ringshausen

¹²Klinik für Pneumologie, Medizinische Hochschule Hannover, Hannover

¹⁹Deutsches Zentrum für Lungenforschung

,

C. F. Vogelmeier

¹³Klinik für Pneumologie, Universitätsklinikum Marburg, Marburg

¹⁹Deutsches Zentrum für Lungenforschung

,

N. Reinmuth

¹⁴Asklepios Fachkliniken München-Gauting, Thorakale Onkologie, Gauting

¹⁹Deutsches Zentrum für Lungenforschung

,

M. Reck

²LungenClinic Großhansdorf, Großhansdorf

¹⁹Deutsches Zentrum für Lungenforschung

,

J. Gottlieb

¹²Klinik für Pneumologie, Medizinische Hochschule Hannover, Hannover

¹⁹Deutsches Zentrum für Lungenforschung

,

S. Konstantinides

¹⁵Centrum für Thrombose und Hämostase (CTH), Universitätsmedizin Mainz, Mainz

,

F. J. Meyer

¹⁶Lungenzentrum München (Bogenhausen-Harlaching), München Klinik, München

,

H. Worth

¹⁷Facharztforum Fürth, Fürth

,

W. Windisch

¹⁸Lungenklinik, Kliniken der Stadt Köln GmbH, Lehrstuhl für Pneumologie der Universität Witten-Herdecke

,

T. Welte

¹²Klinik für Pneumologie, Medizinische Hochschule Hannover, Hannover

¹⁹Deutsches Zentrum für Lungenforschung

,

T. Bauer

⁷Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Buitrago-Garcia D, Egli-Gany D, Counotte MJ. et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med 2020; 17: e1003346
2 Robert-Koch-Institut (RKI). 2020 https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.html
3 He X, Lau EHY, Wu P. et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020; 26: 672-675
4 Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med 2020; 383: 1757-1766
5 Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med 2020;
6 Karagiannidis C, Mostert C, Hentschker C. et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. The Lancet Respiratory Medicine 2020; 8: 853-862
7 Windisch W, Weber-Carstens S, Kluge S. et al. Invasive and Non-Invasive Ventilation in Patients With COVID-19. Dtsch Arztebl Int 2020; 117: 528-533
8 Kluge S, Janssens U, Welte T. et al. German recommendations for treatment of critically ill patients with COVID-19-version 3: S1-guideline. Anaesthesist 2020; 69: 653-664
9 Ackermann M, Verleden SE, Kuehnel M. et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 2020; 383: 120-128
10 Bilaloglu S, Aphinyanaphongs Y, Jones S. et al. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. JAMA 2020; 324: 799-801
11 Nicolai L, Leunig A, Brambs S. et al. Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy. Circulation 2020; 142: 1176-1189
12 Sokolowska M, Lukasik ZM, Agache I. et al. Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives – A report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy 2020; 75: 2445-2476
13 Schmidt M, Hajage D, Lebreton G. et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. The Lancet Respiratory Medicine 2020; 8: 1121-1131
14 Pfeifer M, Ewig S, Voshaar T. et al. Position Paper for the State of the Art Application of Respiratory Support in Patients with COVID-19 – German Respiratory Society. Pneumologie 2020; 74: 337-357
15 Kolditz M, Tesch F, Mocke L. et al. Burden and risk factors of ambulatory or hospitalized CAP: A population based cohort study. Respir Med 2016; 121: 32-38
16 Salje H, Tran Kiem C, Lefrancq N. et al. Estimating the burden of SARS-CoV-2 in France. Science 2020; 369: 208-211
17 Gudbjartsson DF, Norddahl GL, Melsted P. et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med 2020; 383: 1724-1734
18 Pastor-Barriuso R, Perez-Gomez B, Hernan MA. et al. Infection fatality risk for SARS-CoV-2: a nationwide seroepidemiological study in the non-institutionalized population of Spain. 2020 https://www.medrxiv.org/content/101101/2020080620169722v2
19 Ward H, Atchison CJ, Whitaker M. et al. Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults. 2020 https://www.medrxiv.org/content/101101/2020081220173690v2
20 Rajgor DD, Lee MH, Archuleta S. et al. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis 2020; 20: 776-777
21 Williamson EJ, Walker AJ, Bhaskaran K. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584: 430-436
22 Knight SR, Ho A, Pius R. et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ 2020; 370: m3339
23 Docherty AB, Harrison EM, Green CA. et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020; 369: m1985
24 Petrilli CM, Jones SA, Yang J. et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020; 369: m1966
25 Nachtigall I, Lenga P, Jóźwiak K. et al. Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study. Clin Microbiol Infect 2020;
26 Clift AK, Coupland CAC, Keogh RH. et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ 2020; 371: m3731
27 Zádori N, Váncsa S, Farkas N. et al. The negative impact of comorbidities on the disease course of COVID-19. Intensive Care Med 2020; 46: 1784-1786
28 Chen R, Liang W, Jiang M. et al. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. Chest 2020; 158: 97-105
29 Richardson S, Hirsch JS, Narasimhan M. et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020; 323: 2052-2059
30 Arons MM, Hatfield KM, Reddy SC. et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. N Engl J Med 2020; 382: 2081-2090
31 Izquierdo JL, Almonacid C, González Y. et al. The Impact of COVID-19 on Patients with Asthma. Eur Respir J 2020;
32 Calmes D, Graff S, Maes N. et al. Asthma and COPD Are Not Risk Factors for ICU Stay and Death in Case of SARS-CoV2 Infection. The Journal of Allergy and Clinical Immunology In practice 2020;
33 Grandbastien M, Piotin A, Godet J. et al. SARS-CoV-2 Pneumonia in Hospitalized Asthmatic Patients Did Not Induce Severe Exacerbation. The Journal of Allergy and Clinical Immunology In practice 2020; 8: 2600-2607
34 Santos MM, Lucena EES, Lima KC. et al. Survival and predictors of deaths of patients hospitalised due to COVID-19 from a retrospective and multicentre cohort study in Brazil. Epidemiol Infect 2020; 148: e198
35 Avdeev S, Moiseev S, Brovko M. et al. Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19. Allergy 2020; 75: 2703-2704
36 Abe K, Miyawaki A, Nakamura M. et al. Trends in hospitalizations for asthma during the COVID-19 outbreak in Japan. The Journal of Allergy and Clinical Immunology In practice 2020;
37 Chhiba KD, Patel GB, Vu THT. et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol 2020; 146: 307-314.e304
38 Lieberman-Cribbin W, Rapp J, Alpert N. et al. The Impact of Asthma on Mortality in Patients With COVID-19. Chest 2020;
39 Lovinsky-Desir S, Deshpande DR, De A. et al. Asthma among hospitalized patients with COVID-19 and related outcomes. J Allergy Clin Immunol 2020; 146: 1027-1034.e1024
40 Robinson LB, Fu X, Bassett IV. et al. COVID-19 severity in hospitalized patients with asthma: A matched cohort study. The Journal of Allergy and Clinical Immunology In practice 2020;
41 Rosenthal JA, Awan SF, Fintzi J. et al. Asthma Is Associated with Increased Risk of Intubation but Not Hospitalization or Death in COVID-19. Ann Allergy Asthma Immunol 2020;
42 Wang L, Foer D, Bates DW. et al. Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19. J Allergy Clin Immunol 2020; 146: 808-812
43 Lommatzsch M, Stoll P, Virchow JC. COVID-19 in a patient with severe asthma treated with Omalizumab. Allergy 2020; 75: 2705-2708
44 Renner A, Marth K, Patocka K. et al. COVID-19 in a severe eosinophilic asthmatic receiving benralizumab – a case study. J Asthma 2020; 1-3
45 Förster-Ruhrmann U, Szczepek AJ, Bachert C. et al. COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab. J Allergy Clin Immunol 2020; 146: 218-220.e212
46 Hanon S, Brusselle G, Deschampheleire M. et al. COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry. Eur Respir J 2020;
47 Haroun-Díaz E, Vázquez de la Torre M, Ruano FJ. et al. Severe asthma during the COVID-19 pandemic: Clinical observations. The Journal of Allergy and Clinical Immunology In practice 2020; 8: 2787-2789
48 Antonicelli L, Tontini C, Manzotti G. et al. Severe asthma in adults does not significantly affect the outcome of COVID-19 disease: Results from the Italian Severe Asthma Registry. Allergy 2020;
49 Matucci A, Caminati M, Vivarelli E. et al. COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey. Allergy 2020;
50 Bhalla A, Mukherjee M, Radford K. et al. Dupilumab, severe asthma airway responses, and SARS-CoV-2 serology. Allergy 2020;
51 Yang JM, Koh HY, Moon SY. et al. Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. J Allergy Clin Immunol 2020; 146: 790-798
52 Choi YJ, Park JY, Lee HS. et al. Effect of Asthma and Asthma Medication on the Prognosis of Patients with COVID-19. Eur Respir J 2020;
53 Wang Y, Ao G, Qi X. et al. The association between COVID-19 and asthma: A systematic review and meta-analysis. Clin Exp Allergy 2020; 50: 1274-1277
54 Yao Y, Wang H, Liu Z. Expression of ACE2 in airways: Implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases. Clin Exp Allergy 2020;
55 Farne H, Singanayagam A. Why asthma might surprisingly protect against poor outcomes in COVID-19. Eur Respir J 2020;
56 Keswani A, Dhana K, Rosenthal JA. et al. Atopy is predictive of a decreased need for hospitalization for coronavirus disease 2019. Ann Allergy Asthma Immunol 2020; 125: 479-481
57 Matusiak M, Schürch CM. Expression of SARS-CoV-2 entry receptors in the respiratory tract of healthy individuals, smokers and asthmatics. Respir Res 2020; 21: 252
58 Jackson DJ, Busse WW, Bacharier LB. et al. Association of Respiratory Allergy, Asthma and Expression of the SARS-CoV-2 Receptor, ACE2. J Allergy Clin Immunol 2020;
59 Hegde S. Does asthma make COVID-19 worse?. Nat Rev Immunol 2020;
60 Bradding P, Richardson M, Hinks TSC. et al. ACE2, TMPRSS2, and furin gene expression in the airways of people with asthma-implications for COVID-19. J Allergy Clin Immunol 2020; 146: 208-211
61 Camiolo M, Gauthier M, Kaminski N. et al. Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype. J Allergy Clin Immunol 2020; 146: 315-324.e317
62 Kimura H, Francisco D, Conway M. et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol 2020; 146: 80-88.e88
63 Schultze A, Walker AJ, MacKenna B. et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. The Lancet Respiratory Medicine 2020; 8: 1106-1120
64 Peters MC, Sajuthi S, Deford P. et al. COVID-19 Related Genes in Sputum Cells in Asthma: Relationship to Demographic Features and Corticosteroids. Am J Respir Crit Care Med 2020;
65 Maes T, Bracke K, Brusselle GG. COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?. Am J Respir Crit Care Med 2020; 202: 8-10
66 Klimek L, Jutel M, Akdis C. et al. Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. Allergy 2020; 75: 1546-1554
67 Carugno A, Gambini DM, Raponi F. et al. COVID-19 and biologics for psoriasis: a high-epidemic area experience - Bergamo, Lombardy, Italy. J Am Acad Dermatol 2020; 83: 292-294
68 Monti S, Balduzzi S, Delvino P. et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020; 79: 667-668
69 Maijers I, Kearns N, Harper J. et al. Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma. Eur Respir J 2020; 55: 1901147
70 Alqahtani JS, Oyelade T, Aldhahir AM. et al. Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. PLoS One 2020; 15: e0233147
71 Peng Y, Meng K, He M. et al. Clinical Characteristics and Prognosis of 244 Cardiovascular Patients Suffering From Coronavirus Disease in Wuhan, China. J Am Heart Assoc 2020; 9: e016796
72 Zhang P, Zhu L, Cai J. et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res 2020; 126: 1671-1681
73 Fosbøl EL, Butt JH, Østergaard L. et al. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. JAMA 2020; 324: 168-177
74 Colombo C, Burgel PR, Gartner S. et al. Impact of COVID-19 on people with cystic fibrosis. The Lancet Respiratory Medicine 2020; 8: e35-e36
75 McClenaghan E, Cosgriff R, Brownlee K. et al. The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. J Cyst Fibros 2020;
76 Ringshausen FC, Hellmuth T, Dittrich AM. Evidence-based treatment of cystic fibrosis. Internist (Berl) 2020;
77 Griese M, Costa S, Linnemann RW. et al. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for ≥ 24 Weeks in People With CF and ≥ 1 F508del Allele: Interim Results of an Open-Label Phase Three Clinical Trial. Am J Respir Crit Care Med 2020;
78 Drake TM, Docherty AB, Harrison EM. et al. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease: An International Multicenter Study. Am J Respir Crit Care Med 2020;
79 Sweiss NJ, Korsten P, Syed HJ. et al. When the Game Changes: Guidance to Adjust Sarcoidosis Management During the Coronavirus Disease 2019 Pandemic. Chest 2020; 158: 892-895
80 Collard HR, Richeldi L, Kim DS. et al. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J 2017; 49: 1601339
81 Ley B, Swigris J, Day BM. et al. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2017; 196: 756-761
82 George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. The Lancet Respiratory Medicine 2020; 8: 807-815
83 Morgenthau AS, Levin MA, Freeman R. et al. Moderate or Severe Impairment in Pulmonary Function is Associated with Mortality in Sarcoidosis Patients Infected with SARS‑CoV‑2. Lung 2020; 198: 771-775
84 Gianfrancesco M, Hyrich KL, Al-Adely S. et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020; 79: 859-866
85 Gianfrancesco M, Hyrich KL, Yazdany J. et al. Response to: ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’ by Györfi et al. Ann Rheum Dis 2020;
86 Landewé RB, Machado PM, Kroon F. et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis 2020; 79: 851-858
87 Aigner C, Dittmer U, Kamler M. et al. COVID-19 in a lung transplant recipient. The Journal of Heart and Lung Transplantation 2020; 39: 610-611
88 Pereira MR, Mohan S, Cohen DJ. et al. COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter. Am J Transplant 2020; 20: 1800-1808
89 Fernandez-Ruiz M, Andres A, Loinaz C. et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant 2020; 20: 1846-1858
90 Akalin E, Azzi Y, Bartash R. et al. Covid-19 and Kidney Transplantation. N Engl J Med 2020; 382: 2475-2477
91 Latif F, Farr MA, Clerkin KJ. et al. Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019. JAMA Cardiol 2020;
92 Liang W, Guan W, Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The Lancet Oncology 2020; 21: 335-337
93 Tian J, Yuan X, Xiao J. et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. The Lancet Oncology 2020; 21: 893-903
94 Kuderer NM, Choueiri TK, Shah DP. et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020; 395: 1907-1918
95 Albiges L, Foulon S, Bayle A. et al. Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. Nature Cancer 2020; 1: 965-975
96 Rugge M, Zorzi M, Guzzinati S. SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer. Nature Cancer 2020; 1: 784-788
97 Subbiah V. A global effort to understand the riddles of COVID-19 and cancer. Nature Cancer 2020; 1: 943-945
98 Garassino MC, Whisenant JG, Huang LC. et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. The Lancet Oncology 2020; 21: 914-922
99 Whisenant JG, Trama A, Torri V. et al. TERAVOLT: Thoracic Cancers International COVID-19 Collaboration. Cancer Cell 2020; 37: 742-745
100 Horn L, Whisenant JG, Torri V. et al. Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival. Journal of Clinical Oncology 2020; 38: LBA111-LBA111
101 Baena Espinar J, Torri V, Whisenant J. et al. LBA75 Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion). Ann Oncol 2020; 31: S1204-S1205
102 Luo J, Rizvi H, Preeshagul IR. et al. COVID-19 in patients with lung cancer. Ann Oncol 2020; 31: 1386-1396
103 Sereno M, Gutierrez-Gutierrez G, Sandoval C. et al. A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: Is immunosuppression a risk factor for SARS-COV2 infection?. Lung Cancer 2020; 145: 213-215
104 Calabro L, Peters S, Soria JC. et al. Challenges in lung cancer therapy during the COVID-19 pandemic. The Lancet Respiratory Medicine 2020; 8: 542-544
105 Curigliano G, Banerjee S, Cervantes A. et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol 2020; 31: 1320-1335
106 Büchner N, Woehrle H, Dellweg D. et al. Management of diagnostic procedures and treatment of sleep related breathing disorders in the context of the coronavirus pandemic. Somnologie (Berl) 2020; 1-11
107 Pfeifer M, Ewig S, Voshaar T. et al. Position Paper for the State-of-the-Art Application of Respiratory Support in Patients with COVID-19. Respiration 2020; 99: 521-542
108 Windisch W, Dellweg D, Geiseler J. et al. Prolonged Weaning from Mechanical Ventilation: Results from Specialized Weaning Centers. Dtsch Arztebl Int 2020; 117: 197-204
109 Bajwah S, Wilcock A, Towers R. et al. Managing the supportive care needs of those affected by COVID-19. Eur Respir J 2020; 55: 2000815
110 Ravimohan S, Kornfeld H, Weissman D. et al. Tuberculosis and lung damage: from epidemiology to pathophysiology. Eur Respir Rev 2018; 27: 170077
111 Gupte AN, Paradkar M, Selvaraju S. et al. Assessment of lung function in successfully treated tuberculosis reveals high burden of ventilatory defects and COPD. PLoS One 2019; 14: e0217289
112 Tamuzi JL, Ayele BT, Shumba CS. et al. Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence. BMC Infect Dis 2020; 20: 744
113 Gupta N, Ish P, Gupta A. et al. A profile of a retrospective cohort of 22 patients with COVID-19 and active/treated tuberculosis. Eur Respir J 2020; 56: 2003408
114 Tadolini M, Codecasa LR, García-García JM. et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J 2020; 56: 2001398
115 Ong CWM, Migliori GB, Raviglione M. et al. Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). Eur Respir J 2020; 56: 2001727
116 Cilloni L, Fu H, Vesga JF. et al. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. EClinicalMedicine 2020; 28: 100603
117 Otto-Knapp R, Häcker B, Breuer C. et al. DZK Recommendations for Tuberculosis, BCG and COVID-19 in Germany – (Official Abbreviation of Coronavirus Disease 2019 Caused by the New Coronavirus SARS-CoV-2). Pneumologie 2020; 74: 412-416
118 OʼNeill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19?. Nat Rev Immunol 2020; 20: 335-337
119 Curtis N, Sparrow A, Ghebreyesus TA. et al. Considering BCG vaccination to reduce the impact of COVID-19. Lancet 2020; 395: 1545-1546
120 Joy M, Malavika B, Asirvatham ES. et al. Is BCG associated with reduced incidence of COVID-19? A meta-regression of global data from 160 countries. Clin Epidemiol Glob Health 2020;
121 Moorlag S, Arts RJW, van Crevel R. et al. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect 2019; 25: 1473-1478
122 Middeldorp S, Coppens M, van Haaps TF. et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18: 1995-2002
123 Wichmann D, Sperhake JP, Lütgehetmann M. et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med 2020; 173: 268-277
124 Menter T, Haslbauer JD, Nienhold R. et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology 2020; 77: 198-209
125 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-1062
126 Lodigiani C, Iapichino G, Carenzo L. et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 2020; 191: 9-14
127 Klok FA, Kruip M, van der Meer NJM. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-147
128 Cui S, Chen S, Li X. et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020; 18: 1421-1424
129 Nadkarni GN, Lala A, Bagiella E. et al. Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. J Am Coll Cardiol 2020; 76: 1815-1826
130 Ständiger Arbeitskreis der Kompetenz- und Behandlungszentren für Krankheiten durch hochpathogene Erreger (STAKOB). Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit COVID-19. https://pneumologie.de/fileadmin/user_upload/COVID-19/20201105_STAKOB_Covid-19_Therapie_Diagnose.pdf Stand: 05.11.2020
131 Thachil J, Tang N, Gando S. et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020; 18: 1023-1026
132 European Society of Cardiology (ESC). ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. 2020 https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance?hit=home&urlorig=/vgn-ext-templating
133 Gerotziafas GT, Catalano M, Colgan MP. et al. Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thromb Haemost 2020;
134 Bikdeli B, Madhavan MV, Jimenez D. et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol 2020; 75: 2950-2973
135 Worth H, Bock R, Frisch M. et al. Group Training of Patients with Chronic Lung Diseases under Outpatient Conditions – Recommendations of the Working Group Lung Sports in Germany and the German Airways League. Pneumologie 2020;

Risikoabschätzung bei Patienten mit chronischen Atemwegs- und Lungenerkrankungen im Rahmen der SARS-CoV-2-Pandemie[*]

Risikoabschätzung bei Patienten mit chronischen Atemwegs- und Lungenerkrankungen im Rahmen der SARS-CoV-2-Pandemie^[*]